Therefore, we showed that the extent of MGMT promoter methylation also had predictive value in IDH-mutant GBM receiving TMZ therapy, and that the optimal cutoff value of MGMT promoter methylation should be dramatically higher than that used for IDH-wildtype cases. Here, IDH1 is linked to glioblastoma.